Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price target hoisted by Royal Bank Of Canada from $100.00 to $103.00 in a research note issued to investors on Tuesday,MarketScreener reports. The firm presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target suggests a potential downside of 16.59% from the company’s current price.

A number of other equities analysts have also weighed in on GILD. TD Cowen increased their price target on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Wolfe Research reiterated an “outperform” rating and issued a $150.00 target price on shares of Gilead Sciences in a research note on Monday, December 15th. Sanford C. Bernstein set a $135.00 price target on shares of Gilead Sciences and gave the company an “outperform” rating in a report on Monday, December 29th. Rothschild & Co Redburn upped their price target on Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $133.28.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $123.49 on Tuesday. The business’s 50-day simple moving average is $123.49 and its 200-day simple moving average is $118.20. The firm has a market capitalization of $153.22 billion, a P/E ratio of 19.18, a P/E/G ratio of 0.66 and a beta of 0.33. Gilead Sciences has a 1-year low of $91.84 and a 1-year high of $128.70. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts predict that Gilead Sciences will post 7.95 EPS for the current year.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the transaction, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This represents a 1.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at $1,115,713.60. This trade represents a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 136,757 shares of company stock worth $16,951,612. Corporate insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Hedge funds have recently added to or reduced their stakes in the company. GoalVest Advisory LLC increased its stake in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC purchased a new position in Gilead Sciences during the 3rd quarter valued at about $26,000. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences during the second quarter valued at approximately $27,000. Putney Financial Group LLC lifted its stake in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. Finally, Howard Hughes Medical Institute purchased a new position in Gilead Sciences during the second quarter worth about $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.